The company plans to launch mProbe Korea next month to develop a solution for diagnosing type 2 diabetes and develop ways to predict the risk of premature birth. (image: Korea Bizwire)
DAEJEON, Jan. 22 (Korea Bizwire) — According to the Korea Institute of Science and Technology Information (KISTI) on Monday, mProbe will be signing a Cooperative Research and Development Agreement (CRADA) for commercializing technologies at the KISTI headquarters in Daejeon on January 22.
Stanford University Investment Company, also known as mProbe, was established in 2016 based on its metabolome and proteome analysis technology.
The Stanford venture seems to be strengthening its influence by acquiring in vitro diagnosis related businesses in the U.S. and establishing branches in China, Hong Kong, and Taiwan.
The company plans to launch mProbe Korea next month to develop a solution for diagnosing type 2 diabetes and develop ways to predict the risk of premature birth.
Both KISTI and mProbe are expecting great results and hope to contribute to new industries as the partnership represents the combination of KISTI’s extensive biomedical databases and its world-class supercomputer with the expertise of Stanford University’s research team.
Kevin Lee (kevinlee@koreabizwire.com)
